|
|
Volumn 24, Issue 3, 2006, Pages 528-529
|
|
Overstated conclusions of a pooled analysis of bevacizumab in colon cancer [1]
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
FLUOROURACIL;
FOLINIC ACID;
IRINOTECAN;
PLACEBO;
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
CANCER SURVIVAL;
CLINICAL TRIAL;
COLON CANCER;
CONTROLLED CLINICAL TRIAL;
DISEASE FREE SURVIVAL;
DRUG EFFICACY;
HUMAN;
LETTER;
METASTASIS;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
TREATMENT RESPONSE;
COLON TUMOR;
META ANALYSIS;
METHODOLOGY;
NOTE;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
STANDARD;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS, PHASE II;
CLINICAL TRIALS, PHASE III;
COLONIC NEOPLASMS;
FLUOROURACIL;
HUMANS;
LEUCOVORIN;
META-ANALYSIS;
RANDOMIZED CONTROLLED TRIALS;
RESEARCH DESIGN;
TREATMENT OUTCOME;
|
|
EID: 33644837728
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2005.04.3570 Document Type: Letter |
|
Times cited : (8)
|
|
References (5)
|
